A brilliant colleague once shared a story with me about a psychiatrist who used a fascinating metaphor to describe the onset of effect of selective serotonin reuptake inhibitors (SSRIs) to his patients. "Think of it like a football stadium," the psychiatrist would say. "You flip the switch, and the lights don't come on immediately. One by one, the banks of lights flicker to life until the entire field is lit."
This simple analogy—a concept we call a 'behavioral belief'—has helped countless patients stick with a treatment that offers no immediate reward and often comes with side effects before benefits. Without it, many might have abandoned their antidepressant medicines too soon. With it, they had a rationale (and a mental construct) to stay the course.
This story, while seemingly trivial, captures an underleveraged tool in pharmaceutical marketing: the power of behavioral beliefs to help form and reinforce customer habits.
In neuroscience, we understand habits as the result of deeply ingrained neural loops involving the basal ganglia, dopamine-mediated reinforcement, and cortical cues. These biological mechanisms align surprisingly well with the habit models made popular by Charles Duhigg's "cue-routine-reward" loop and Nir Eyal's "trigger-action-reward" model. These models work beautifully in consumer tech, fast food, fitness, and even finance. But in healthcare—and pharma in particular—this loop often breaks down.
Why?
Because in pharma, the "reward" is often delayed, invisible, or even negative. A patient taking a statin doesn’t feel anything—unless it’s muscle pain. A psoriasis treatment might cause flares before clearing. An oncologist might prescribe an immunotherapy knowing that scans could show pseudo-progression before improvement. These are not intuitive feedback loops. They don’t reinforce habits. They challenge them.
Contrast this with the user experience of modern consumer electronics. Select an app on your smartphone, and you get what you want instantly: the news, weather, directions, entertainment. It's an immediate on switch that gives us a sense of reward. A smartwatch taps your wrist the moment you close your activity ring. These technologies essentially train users to expect immediate, frictionless feedback—a dynamic pharma products rarely provide.
Consider the recent market challenges surrounding dual orexin receptor antagonists (DORAs) in treating insomnia. Compared to "z-drugs," sedative hypnotics like Ambien, which create an immediate knock-out effect, DORAs work gradually by modulating wakefulness. They require consistent nightly use and time to achieve efficacy.
For patients conditioned to expect an immediate impact, the feedback from DORAs felt like failure. Physicians began reporting skepticism from patients who didn't "feel" the drug working the way Ambien did. In this case, a lack of immediate, visceral feedback created a belief gap.
By leveraging the right behavioral belief—such as, "This medicine helps your brain find its natural rhythm again over time" or "The absence of a knockout effect means you're regaining real sleep, not sedation"—the interpretive frame could shift from doubt to understanding. Belief can define the success or failure of an experience.
From a neuroscientific standpoint, belief formation is a process of neural encoding in the prefrontal cortex that helps us anticipate outcomes and assign meaning. In complex medical treatments, where feedback is inconsistent or ambiguous, beliefs serve as the scaffolding for behavioral persistence.
We at ThinkGen call these constructs behavioral beliefs—cognitively constructed explanations that help individuals interpret their experience and assign value to it. They transform counterintuitive or negative feedback into evidence of progress. Outside healthcare, the belief "No pain, no gain" accomplishes exactly this. Muscle soreness after a workout is recast as a positive sign of effort and growth.
In pharma, behavioral beliefs function similarly. They help physicians explain, for example, why a migraine preventive needs to be taken daily even if the patient doesn’t experience daily migraines. Or why flu-like symptoms after vaccination are not side effects to fear, but signs of immune engagement. Or why an Alzheimer's treatment isn't going to help the patient's symptoms to improve, but rather to slow their decline.
Behavioral beliefs are essential to the healthcare journey today for several reasons:
More often than not, pharma marketing defaults to rational education—data, mechanisms of action, comparative tables. But neuroscience tells us that belief change occurs through emotional salience, storytelling, and repetition—not through bullet points.
Belief engineering is the discipline of shaping the mental models that drive adherence, prescribing, and usage. Ask:
It’s not enough to disseminate facts. We must design beliefs that make behavior sustainable.
Each of these beliefs changes the internal narrative from threat to reassurance—from doubt to trust.
At ThinkGen, our Habit Lens approach integrates behavioral science and neuroscience to diagnose where the habit loop breaks down and what beliefs are needed to complete it. In pharma, the loop is often incomplete because of challenges in feedback interpretation.
We help clients uncover habit-critical beliefs:
These aren’t just insights. They’re strategic imperatives.
Pharma marketers must embrace belief engineering as a foundational strategy:
This approach aligns closely with the evolving field of neuromarketing—the application of neuroscience principles to influence behavior. Though regulatory caution has made adoption slow in pharma, the discipline offers tremendous value when applied responsibly: to inform, not manipulate.
Because if we fail to close the belief gap, even the most effective therapies may fail in the marketplace—not for lack of science, but for lack of meaning.
In a world of complex biology, delayed outcomes, and uncertain feedback, we must shift from behavioral tactics to belief strategy. That means designing for cognition, not just compliance.
When we help customers build explanatory beliefs, we give them the psychological structure to persist, adapt, and succeed. That’s not just good marketing—it’s good medicine.
Let’s shape belief, not just behavior.